Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06906367 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Patients With Fabry Disease (US Specific)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 8 sitesv14
  2. Site details revised at 1 of 8 sitesv13
  3. Site details revised at 1 of 8 sitesv12
  4. Study sites: 7 to 8v11
  5. Site details revised at 1 of 7 sitesv10
Show 8 earlier versionsHide 8 earlier versions
  1. Start date changed from estimate of Feb 2026 to Feb 13, 2026v9
  2. Start date: Jan 2026 to Feb 2026
    • Site details revised at 2 of 7 sites
    v8
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2025 to Jan 2026
    • Site details revised at 7 of 7 sites
    v7
  4. Start date: Oct 2025 to Dec 2025
    • Study sites: 4 to 7
    v6
  5. Start date: Jul 2025 to Oct 2025v5
  6. Study sites: 0 to 4v4
  7. Start date: May 2025 to Jul 2025v3
  8. Secondary endpoints revised (17)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.
Trial Details
NCT Number NCT06906367
Lead Sponsor Amicus Therapeutics
Conditions
(from sponsor)		 Fabry Disease
Related terms Fabry Disease
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov